Neurodegenerative Disease CRISPR Models for Drug Discovery

Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), represent a growing global health crisis. According to the World Health Organization (WHO), dementia, primarily caused by AD, affects over 55 million people worldwide, with nearly 10 million new cases each year. PD is the fastest-growing neurological disorder, with prevalence doubling in the past 25 years. ALS has an incidence of approximately 1-2 per 100,000 person-years. These diseases are characterized by progressive neuronal loss, leading to cognitive decline, motor dysfunction, and ultimately death. The lack of disease-modifying therapies underscores the urgent need for better research models. Key risk factors include age, genetics (e.g., APOE4 for AD, GBA1 for PD), and environmental exposures. The 5-year survival rate for ALS is approximately 20%, while AD and PD have variable but prolonged courses.

Neurodegenerative diseases are ideal for mechanistic studies due to their well-defined genetic subtypes (familial vs. sporadic), the availability of large public datasets (e.g., ADNI, PPMI, Target ALS), and the existence of specific proteinopathies (e.g., amyloid-beta, tau, alpha-synuclein, TDP-43). Key open questions include the role of neuroinflammation, the spread of pathological proteins, and the mechanisms of selective neuronal vulnerability. Gene-edited cell models allow researchers to dissect these pathways in human-relevant systems, bridging the gap between simple overexpression models and complex animal studies.

The pathogenesis of neurodegenerative diseases involves several interconnected pathways:

1. Protein Misfolding and Aggregation:

• • Accumulation of misfolded proteins (e.g., amyloid-beta plaques, tau tangles, alpha-synuclein Lewy bodies, TDP-43 inclusions).
• • Impaired proteostasis (autophagy, ubiquitin-proteasome system).

2. Mitochondrial Dysfunction and Oxidative Stress:

• • Impaired mitochondrial dynamics and bioenergetics.
• • Increased reactive oxygen species (ROS) production.
• • Defective mitophagy.

3. Neuroinflammation:

• • Chronic activation of microglia and astrocytes.
• • Release of pro-inflammatory cytokines (e.g., TNF-alpha, IL-1beta).
• • Complement system activation.

4. Excitotoxicity and Synaptic Dysfunction:

• • Glutamate-mediated neuronal damage.
• • Impaired synaptic plasticity and loss of synapses.
• • Dysregulation of calcium homeostasis.

Data from ClinVar, NCBI Gene, and published literature.

• • Autophagy-Lysosome Pathway: Key nodes include mTOR, TFEB, and Beclin-1. Dysregulation leads to accumulation of protein aggregates.
• • Unfolded Protein Response (UPR): ER stress sensors (PERK, IRE1, ATF6) are activated in AD and PD, leading to apoptosis.
• • Innate Immune Signaling: TLR4, TREM2, and NLRP3 inflammasome activation in microglia drive neuroinflammation.
• • MAPK/ERK Pathway: Hyperactivation contributes to tau phosphorylation and synaptic dysfunction.
• • PI3K/AKT Pathway: Reduced signaling impairs neuronal survival and metabolism.

Organoids offer advantages over 2D cultures by providing a more physiologically relevant 3D environment with multiple cell types (neurons, astrocytes, microglia).

• • Transgenic mouse models: Overexpress human APP (e.g., Tg2576), mutant tau (e.g., P301S), or alpha-synuclein (e.g., A53T).
• • Knock-in mouse models: Express humanized or mutant genes at endogenous levels (e.g., APP NL-G-F, SNCA A53T KI).
• • Induced models: Stereotaxic injection of pre-formed fibrils (PFFs) of alpha-synuclein or tau to induce pathology.
• • Zebrafish models: Transparent, high-throughput; used for genetic screens and drug testing.

CRISPR-Cas9 technology enables the generation of isogenic cell lines with precise genetic modifications, eliminating confounding effects of different genetic backgrounds. Examples include:

• • APP knockout lines: To study the role of APP in amyloid-beta production.
• • SNCA A53T knock-in lines: To model PD-associated alpha-synuclein aggregation.
• • C9orf72 knockout lines: To investigate haploinsufficiency in ALS/FTD.
• • HTT CAG repeat expansion lines: To model HD pathogenesis.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing ready-to-use tools for target validation, drug screening, and mechanistic studies.

CRISPR knockout and knock-in lines are used to validate the functional role of genes identified in GWAS and sequencing studies. For example:

• • TREM2 knockout in iPSC-derived microglia: Demonstrates impaired phagocytosis and increased inflammatory response, linking TREM2 variants to AD risk.
• • LRRK2 G2019S knock-in in SH-SY5Y cells: Shows increased kinase activity and reduced neurite outgrowth, confirming its role in PD.
• • C9orf72 knockout in iPSC-derived neurons: Reveals deficits in autophagy and increased sensitivity to excitotoxicity.

Isogenic pairs (wild-type vs. mutant) enable high-throughput screening for compounds that selectively target mutant cells. For example:

• • LRRK2 G2019S isogenic pairs: Used to screen for LRRK2 kinase inhibitors.
• • SOD1 A4V isogenic pairs: Used to identify compounds that reduce oxidative stress.
• • HTT CAG repeat isogenic pairs: Used to screen for modulators of protein aggregation.

Resistance mechanisms can also be modeled by introducing secondary mutations in target genes.

CRISPR-engineered cells can be used for synthetic lethality screens to identify novel therapeutic targets. For example:

• • CRISPR screens in C9orf72 knockout cells: Identify genes whose loss is selectively lethal in the context of C9orf72 deficiency, revealing potential drug targets.
• • Proteomic analysis of isogenic lines: Identify secreted proteins (e.g., neurofilament light chain, TDP-43) as potential biomarkers.